The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.
Publication
, Journal Article
Hunter, VJ; Daly, L; Helms, M; Soper, JT; Berchuck, A; Clarke-Pearson, DL; Bast, RC
Published in: Am J Obstet Gynecol
October 1990
Fifty-four patients with advanced epithelial ovarian cancer were monitored with serial serum CA 125 levels after surgical cytoreduction and during multi-agent chemotherapy with cisplatin-containing regimens. CA 125 half-life of less than 20 days was associated with prolonged overall survival (p less than 0.015). In those patients who eventually were found to be disease-free at surgical surveillance procedures, normalization of serum CA 125 levels to less than 35 U/ml within 65 days of primary operation also suggested an improved survival (p less than 0.059).
Duke Scholars
Published In
Am J Obstet Gynecol
DOI
ISSN
0002-9378
Publication Date
October 1990
Volume
163
Issue
4 Pt 1
Start / End Page
1164 / 1167
Location
United States
Related Subject Headings
- Time Factors
- Prognosis
- Ovarian Neoplasms
- Obstetrics & Reproductive Medicine
- Middle Aged
- Humans
- Half-Life
- Follow-Up Studies
- Female
- Cyclophosphamide
Citation
APA
Chicago
ICMJE
MLA
NLM
Hunter, V. J., Daly, L., Helms, M., Soper, J. T., Berchuck, A., Clarke-Pearson, D. L., & Bast, R. C. (1990). The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol, 163(4 Pt 1), 1164–1167. https://doi.org/10.1016/0002-9378(90)90680-6
Hunter, V. J., L. Daly, M. Helms, J. T. Soper, A. Berchuck, D. L. Clarke-Pearson, and R. C. Bast. “The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.” Am J Obstet Gynecol 163, no. 4 Pt 1 (October 1990): 1164–67. https://doi.org/10.1016/0002-9378(90)90680-6.
Hunter VJ, Daly L, Helms M, Soper JT, Berchuck A, Clarke-Pearson DL, et al. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol. 1990 Oct;163(4 Pt 1):1164–7.
Hunter, V. J., et al. “The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.” Am J Obstet Gynecol, vol. 163, no. 4 Pt 1, Oct. 1990, pp. 1164–67. Pubmed, doi:10.1016/0002-9378(90)90680-6.
Hunter VJ, Daly L, Helms M, Soper JT, Berchuck A, Clarke-Pearson DL, Bast RC. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol. 1990 Oct;163(4 Pt 1):1164–1167.
Published In
Am J Obstet Gynecol
DOI
ISSN
0002-9378
Publication Date
October 1990
Volume
163
Issue
4 Pt 1
Start / End Page
1164 / 1167
Location
United States
Related Subject Headings
- Time Factors
- Prognosis
- Ovarian Neoplasms
- Obstetrics & Reproductive Medicine
- Middle Aged
- Humans
- Half-Life
- Follow-Up Studies
- Female
- Cyclophosphamide